SCHEMBL1981191

SCHEMBL1981191

CCOC(=O)C1(NC(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.53
KDM4E B2RXH2 2/20 0.47
OPRM1 P35372 1/20 0.47
LMNA P02545 1/20 0.47
FPR2 P25090 1/20 0.46
SCN9A Q15858 1/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CASP3 P42574 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SPHK1 Q9NYA1 4/20 0.43
EPHX2 P34913 1/20 0.43
PPARG P37231 1/20 0.43
RAB9A P51151 2/20 0.43
SPHK2 Q9NRA0 2/20 0.42
CHRM1 P11229 1/20 0.42
HPGD P15428 2/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1976788 0.86 SMN1; SMN2 (0.55) DGAT2KDM4EOPRM1LMNAMAPT
SCHEMBL1740344 0.85 SMN1; SMN2 (0.50) DGAT2KDM4EOPRM1KMT2AMEN1
SCHEMBL1974968 0.84 PLK1 (0.55) KDM4ELMNAMAPTSPHK1RAB9A
SCHEMBL1992821 0.83 ALOX15 (0.50) DGAT2LMNAKMT2AMEN1SPHK1
SCHEMBL1976483 0.81 EPHX2 (0.47) SPHK1EPHX2ALDH1A1
SCHEMBL12287782 0.80 DGAT2 (0.42) DGAT2KDM4EOPRM1LMNAFPR2
SCHEMBL16496185 0.78 WNT3A (0.45) DGAT2FPR2SCN9A
SCHEMBL3499976 0.77 DGAT2 (0.44) DGAT2KDM4EOPRM1LMNAFPR2
SCHEMBL2540067 0.77 BDKRB1 (0.50) DGAT2FPR2SCN9AMAPTKMT2A
SCHEMBL1740298 0.77 KCNK3 (0.46) KDM4EKMT2AMEN1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509981-B1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE LILLY CO ELI (US) 2014-08-06 EP disclosed
EP-2509981-B1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE LILLY CO ELI (US) 2014-08-06 EP disclosed
US-8299061-B2 Inhibitors of diacylglycerol acyltransferase ELI LILLY AND COMPANY (US) 2012-10-30 US disclosed
US-8299061-B2 Inhibitors of diacylglycerol acyltransferase ELI LILLY AND COMPANY (US) 2012-10-30 US disclosed
US-20110144091-A1 Inhibitors of Diacylglycerol Acyltransferase ELI LILLY AND COMPANY (US) 2011-06-16 US disclosed
WO-2011071840-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE ELI LILLY AND COMPANY (US) 2011-06-16 WO disclosed
US-20110144091-A1 Inhibitors of Diacylglycerol Acyltransferase ELI LILLY AND COMPANY (US) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144091-A1 Inhibitors of Diacylglycerol Acyltransferase DGAT1, DGAT2, LCAT DGAT2 2/4885KDM4E 1840/4885OPRM1 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.